No Cover Image

Journal article 162 views 51 downloads

Stimulant and hallucinogenic novel psychoactive substances; an update

F Schifano, A Vento, N Scherbaum, Amira Guirguis Orcid Logo

Expert Review of Clinical Pharmacology, Volume: 16, Issue: 11, Pages: 1109 - 1123

Swansea University Author: Amira Guirguis Orcid Logo

  • 64847.VOR.pdf

    PDF | Version of Record

    © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

    Download (945.92KB)

Check full text

DOI (Published version): 10.1080/17512433.2023.2279192

Abstract

Introduction: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacological issues. Areas covered: The focus here was on: stimulants (e.g. amphetamines, methamphe...

Full description

Published in: Expert Review of Clinical Pharmacology
ISSN: 1751-2433 1751-2441
Published: UK Informa UK Limited 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64847
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-11-01T07:43:55Z
last_indexed 2023-11-01T07:43:55Z
id cronfa64847
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>64847</id><entry>2023-11-01</entry><title>Stimulant and hallucinogenic novel psychoactive substances; an update</title><swanseaauthors><author><sid>b49270b9a0d580cf4f31f9a1b6c93f87</sid><ORCID>0000-0001-8255-0660</ORCID><firstname>Amira</firstname><surname>Guirguis</surname><name>Amira Guirguis</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-11-01</date><deptcode>PHAR</deptcode><abstract>Introduction: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacological issues. Areas covered: The focus here was on: stimulants (e.g. amphetamines, methamphetamine, and pseudoephedrine; phenethylamines; synthetic cathinones; benzofurans; piperazines; aminoindanes; aminorex derivatives; phenmetrazine derivatives; phenidates); classical (e.g. ergolines; tryptamines; psychedelic phenethylamines), and atypical (e.g. PCP/ketamine-like dissociatives) psychedelics. Stimulant and psychedelics are associated with: a) increased central DA levels (psychedelic phenethylamines, synthetic cathinones and stimulants); b) 5-HT receptor subtypes’ activation (psychedelic phenethylamines; recent tryptamine and lysergamide derivatives); and c) antagonist activity at NMDA receptors, (phencyclidine-like dissociatives). Expert opinion: Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites’ analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels.</abstract><type>Journal Article</type><journal>Expert Review of Clinical Pharmacology</journal><volume>16</volume><journalNumber>11</journalNumber><paginationStart>1109</paginationStart><paginationEnd>1123</paginationEnd><publisher>Informa UK Limited</publisher><placeOfPublication>UK</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint>1751-2433</issnPrint><issnElectronic>1751-2441</issnElectronic><keywords>Stimulants, hallucinogens, psychedelics, amphetamine-type stimulants, dissociatives</keywords><publishedDay>22</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-11-22</publishedDate><doi>10.1080/17512433.2023.2279192</doi><url>http://dx.doi.org/10.1080/17512433.2023.2279192</url><notes/><college>COLLEGE NANME</college><department>Pharmacy</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PHAR</DepartmentCode><institution>Swansea University</institution><apcterm>Other</apcterm><funders/><projectreference/><lastEdited>2024-02-02T14:31:22.4786148</lastEdited><Created>2023-11-01T07:23:40.6487507</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>F</firstname><surname>Schifano</surname><order>1</order></author><author><firstname>A</firstname><surname>Vento</surname><order>2</order></author><author><firstname>N</firstname><surname>Scherbaum</surname><order>3</order></author><author><firstname>Amira</firstname><surname>Guirguis</surname><orcid>0000-0001-8255-0660</orcid><order>4</order></author></authors><documents><document><filename>64847__29175__f2f49e598d8d458c9a6a790f37a2a41a.pdf</filename><originalFilename>64847.VOR.pdf</originalFilename><uploaded>2023-12-04T11:23:41.9956882</uploaded><type>Output</type><contentLength>968619</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. Distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 64847 2023-11-01 Stimulant and hallucinogenic novel psychoactive substances; an update b49270b9a0d580cf4f31f9a1b6c93f87 0000-0001-8255-0660 Amira Guirguis Amira Guirguis true false 2023-11-01 PHAR Introduction: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacological issues. Areas covered: The focus here was on: stimulants (e.g. amphetamines, methamphetamine, and pseudoephedrine; phenethylamines; synthetic cathinones; benzofurans; piperazines; aminoindanes; aminorex derivatives; phenmetrazine derivatives; phenidates); classical (e.g. ergolines; tryptamines; psychedelic phenethylamines), and atypical (e.g. PCP/ketamine-like dissociatives) psychedelics. Stimulant and psychedelics are associated with: a) increased central DA levels (psychedelic phenethylamines, synthetic cathinones and stimulants); b) 5-HT receptor subtypes’ activation (psychedelic phenethylamines; recent tryptamine and lysergamide derivatives); and c) antagonist activity at NMDA receptors, (phencyclidine-like dissociatives). Expert opinion: Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites’ analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels. Journal Article Expert Review of Clinical Pharmacology 16 11 1109 1123 Informa UK Limited UK 1751-2433 1751-2441 Stimulants, hallucinogens, psychedelics, amphetamine-type stimulants, dissociatives 22 11 2023 2023-11-22 10.1080/17512433.2023.2279192 http://dx.doi.org/10.1080/17512433.2023.2279192 COLLEGE NANME Pharmacy COLLEGE CODE PHAR Swansea University Other 2024-02-02T14:31:22.4786148 2023-11-01T07:23:40.6487507 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy F Schifano 1 A Vento 2 N Scherbaum 3 Amira Guirguis 0000-0001-8255-0660 4 64847__29175__f2f49e598d8d458c9a6a790f37a2a41a.pdf 64847.VOR.pdf 2023-12-04T11:23:41.9956882 Output 968619 application/pdf Version of Record true © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). true eng https://creativecommons.org/licenses/by-nc-nd/4.0/
title Stimulant and hallucinogenic novel psychoactive substances; an update
spellingShingle Stimulant and hallucinogenic novel psychoactive substances; an update
Amira Guirguis
title_short Stimulant and hallucinogenic novel psychoactive substances; an update
title_full Stimulant and hallucinogenic novel psychoactive substances; an update
title_fullStr Stimulant and hallucinogenic novel psychoactive substances; an update
title_full_unstemmed Stimulant and hallucinogenic novel psychoactive substances; an update
title_sort Stimulant and hallucinogenic novel psychoactive substances; an update
author_id_str_mv b49270b9a0d580cf4f31f9a1b6c93f87
author_id_fullname_str_mv b49270b9a0d580cf4f31f9a1b6c93f87_***_Amira Guirguis
author Amira Guirguis
author2 F Schifano
A Vento
N Scherbaum
Amira Guirguis
format Journal article
container_title Expert Review of Clinical Pharmacology
container_volume 16
container_issue 11
container_start_page 1109
publishDate 2023
institution Swansea University
issn 1751-2433
1751-2441
doi_str_mv 10.1080/17512433.2023.2279192
publisher Informa UK Limited
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
url http://dx.doi.org/10.1080/17512433.2023.2279192
document_store_str 1
active_str 0
description Introduction: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacological issues. Areas covered: The focus here was on: stimulants (e.g. amphetamines, methamphetamine, and pseudoephedrine; phenethylamines; synthetic cathinones; benzofurans; piperazines; aminoindanes; aminorex derivatives; phenmetrazine derivatives; phenidates); classical (e.g. ergolines; tryptamines; psychedelic phenethylamines), and atypical (e.g. PCP/ketamine-like dissociatives) psychedelics. Stimulant and psychedelics are associated with: a) increased central DA levels (psychedelic phenethylamines, synthetic cathinones and stimulants); b) 5-HT receptor subtypes’ activation (psychedelic phenethylamines; recent tryptamine and lysergamide derivatives); and c) antagonist activity at NMDA receptors, (phencyclidine-like dissociatives). Expert opinion: Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites’ analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels.
published_date 2023-11-22T14:31:21Z
_version_ 1789797892590927872
score 11.01753

Similar Items